Evidence map›Paper›PMID 37398301›Full record

ArticlebioRxiv : the preprint server for biology2024

CRISPR screening by AAV episome-sequencing (CrAAVe-seq) is a highly scalable cell type-specific

Biswarathan Ramani, Indigo V L Rose, Noam Teyssier, Andrew Pan, Spencer Danner-Bocks, Tanya Sanghal, Lin Yadanar, Ruilin Tian, Keran Ma, Jorge J Palop and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Biswarathan RamaniInstitute for Neurodegenerative Diseases; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Indigo V L RoseInstitute for Neurodegenerative Diseases; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Noam TeyssierInstitute for Neurodegenerative Diseases; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Andrew PanInstitute for Neurodegenerative Diseases; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Spencer Danner-BocksInstitute for Neurodegenerative Diseases; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Tanya SanghalInstitute for Neurodegenerative Diseases; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Lin YadanarInstitute for Neurodegenerative Diseases; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Ruilin TianInstitute for Neurodegenerative Diseases; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Keran MaGladstone Institute of Neurological Disease, San Francisco, CA, USA.
Jorge J PalopGladstone Institute of Neurological Disease, San Francisco, CA, USA.
Martin KampmannInstitute for Neurodegenerative Diseases; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3819-7019
University of California, San Francisco · USGladstone Institutes · US

Funding

NINDS Research Education Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25)R25NS070680 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOSEPHSON, SCOTT ANDREW · 2010 to 2023
$6.8M
Optogenetic dissection of cellular and circuit mechanisms of network dysfunction and amyloid deposition in mouse models of Alzheimer's disease in vivoRF1AG062234 · NIA · J. DAVID GLADSTONE INSTITUTES · PI PALOP, JORGE J · 2018 to 2021
$3.8M
Predoctoral Training in NeurobiologyT32NS115706 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SAMUEL JEREMY PLEASURE · 2020 to 2026
$3.4M
Molecular mechanisms of selective vulnerability of neurons to tauopathyR01AG082141 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CARLO L CONDELLO, Martin Kampmann · 2023 to 2026
$3.0M
Unraveling the role of the molecular co-chaperone DNAJC7 in protein homeostasis and neurodegenerationK08NS133300 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Biswarathan Ramani · 2024 to 2026
$587k
Functional Alterations of Parvalbumin Interneurons Contributing to Abnormal Network Activity in Alzheimer's Disease Mouse ModelsK99AG062776 · NIA · J. DAVID GLADSTONE INSTITUTES · PI MA, KERAN · 2019 to 2021
$393k
NIA NIH HHS K99 AG062776NIA NIH HHS R01 AG082141NIA NIH HHS RF1 AG062234NINDS NIH HHS K08 NS133300NINDS NIH HHS R25 NS070680NINDS NIH HHS T32 NS115706
6 · The paper itself

Abstract

There is a significant need for scalable CRISPR-based genetic screening methods that can be applied directly in mammalian tissues

Identifiers

PMID37398301
PMCPMC10312723
OpenAlexW4380433380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.